-
1 Comment
Jiangsu Sihuan Bioengineering Co., Ltd is currently in a long term downtrend where the price is trading 18.6% below its 200 day moving average.
From a valuation standpoint, the stock is 14.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Jiangsu Sihuan Bioengineering Co., Ltd's total revenue rose by 5.4% to $118M since the same quarter in the previous year.
Its net income has dropped by 18.0% to $15M since the same quarter in the previous year.
Finally, its free cash flow grew by 22.4% to $12M since the same quarter in the previous year.
Based on the above factors, Jiangsu Sihuan Bioengineering Co., Ltd gets an overall score of 3/5.
| ISIN | CNE0000001P8 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHE |
| CurrencyCode | CNY |
| Beta | 0.47 |
|---|---|
| Market Cap | 2B |
| Target Price | None |
| PE Ratio | None |
| Dividend Yield | None |
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000518.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
